Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2018 ASCO Annual Meeting /
OPTIMISMM trial for refractory multiple myeloma

1st - 5th Jun 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 03.06.18
Views: 3065

Dr Paul Richardson - Dana Farber Cancer Institue, Boston, USA

Prof Richardson speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting about the OPTIMISMM trial assessing the triplet combination of pomalidomide, bortezomib and dexamethasone compared to bortezomib and dexamethasone alone in relapsed/refractory multiple myeloma.

He describes the doses and patient cohort involved in the trial, all of whom had been previously exposed to lenalidomide, and notes significant improvement in response rate and PFS among patients with only one prior line of therapy.

Prof Richardson describes the increase in neutropenia among patients as largely manageable, and that overall survival data is maturing.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation